The US FDA approved updated COVID-19 booster vaccines from Pfizer, Moderna, and Novavax that target currently circulating coronavirus strains but limited usage to adults aged 65 and older or those with underlying conditions increasing risk for severe COVID-19. This regulatory shift prioritizes vulnerable populations and rescinds prior emergency use authorizations for other groups. Changes come amid new CDC guidance recommending shared decision-making for healthy children and pregnant women regarding vaccination.